Would you consider the addition of immunotherapy to chemo for unresectable epithelioid mesothelioma based on the phase 2 PrE0505 and DREAM trial?   

PrE0505 meeting its endpoint of mOS and DREAM meeting its endpoint of PFS6 with durvalumab added to cisplatin/pemetrexed - with phase III  DREAM3R still recruiting. 

We know the checkmate 743 study with ipilimumab/nivolumab did not show significantly improved mOS for epithelioid histology vs chemo (although the trial wasn't powered to detect differences in the subgroups of epithelioid vs non-epithelioid).